Xanthoma of the prostate: A mimicker of high-grade prostate adenocarcinoma

American Journal of Surgical Pathology

Volumn 31, Issue 8, 2007, Pages 1225-1230

  Chuang, Ai Ying ^a,b,c   Epstein, Jonathan I ^c  

^a KOO FOUNDATION SUN YAT SEN CANCER CENTER   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Carcinoma; Granulomatous; Prostate; Prostatitis; Xanthoma

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; CHLORDANE; EOSIN; HEMATOXYLIN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER GRADING; CELL INFILTRATION; CONTROLLED STUDY; CYTOPLASM; FOAM CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MORPHOLOGY; NECROSIS; NEEDLE BIOPSY; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; STROMA; TRANSURETHRAL RESECTION; XANTHOMA;

ADENOCARCINOMA; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; PROSTATE; PROSTATIC NEOPLASMS; XANTHOMATOSIS;

EID: 34547636113     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31802be3c2     Document Type: Article

References (14)

1. Armas OA, Aprikian AG, Melamed J, et al. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol. 1994;18:979-991.
2. Arnold K. Tumor-like histiocytic nodules with chronic prostatitis. Z Urol. 1962;55:219-223.
3. Fox H. Nodular histiocytic prostatitis. J Urol. 1966;96:372-374.
4. Kinoshita M. Xanthomatous carcinoma of the prostate. Z Urol. 1920;14:193-196.
5. Murphy WM, Soloway MS, Barrows GH. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer. 1991;68:821-828.
6. Myhre E. Chronic inflammation of the urinary tract resembling neoplastic growth. Acta Pathol Microbiol Scand. 1963;59:189-194.
7. Nelson RS, Epstein JI. Prostatic carcinoma with abundant xanthomatous cytoplasm. Foamy gland carcinoma. Am J Surg Pathol. 1996;20:419-426.
8. Scherrer MP. Tumor-like proliferation of histiocytic phagocytes in chronic prostatitis. Frankfurter Z Pathol. 1951;62:155-166.
9. Sebo TJ, Bostwick DG, Farrow GM, et al. Prostatic xanthoma: a mimic of prostatic adenocarcinoma. Hum Pathol. 1994;25:386-389.
10. Smith DM, Murphy WM. Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation. Cancer. 1994;73:1472-1477.
11. Tetu B, Srigley JR, Boivin JC, et al. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. Am J Surg Pathol. 1991;15:111-120.
12. Tran TT, Sengupta E, Yang XJ. Prostatic foamy gland carcinoma with aggressive behavior: clinicopathologic, immunohistochemical, and ultrastructural analysis. Am J Surg Pathol. 2001;25:618-623.
13. Vailancourt L, Ttu B, Fradet Y, et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am J Surg Pathol. 1996;20:86-93.
14. Young RH, Srigley JR, Amin MB, et al. Tumors of the prostate gland, seminal vesicles, male urethra, and penis. In: Rosai J, ed. Carcinoma of the Prostate Gland. Washington, DC: Armed Forces Institute of Pathology; 1998.